{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:00:28Z","timestamp":1792839628832,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["JPMH20FC1023"],"award-info":[{"award-number":["JPMH20FC1023"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015542","name":"GlaxoSmithKline Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jhep.2021.04.010","type":"journal-article","created":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T23:37:20Z","timestamp":1618789040000},"page":"565-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":149,"title":["Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-5283","authenticated-orcid":false,"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Hirohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chazouill\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6231-6786","authenticated-orcid":false,"given":"Hajime","family":"Takikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7920-9784","authenticated-orcid":false,"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.04.010_bib1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.04.010_bib2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/hepr.13342","article-title":"Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan","volume":"49","author":"Tanaka","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2021.04.010_bib3","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.dld.2018.11.008","article-title":"Epidemiology of primary biliary cholangitis in Italy: evidence from a real-world database","volume":"51","author":"Marzioni","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2021.04.010_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.04.010_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep4.1170","article-title":"NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid","volume":"2","author":"de Graaf","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2021.04.010_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2019.04.005","article-title":"Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature","volume":"101","author":"Bowlus","year":"2019","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jhep.2021.04.010_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrgastro.2015.12","article-title":"Novel therapeutic targets in primary biliary cirrhosis","volume":"12","author":"Dyson","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.04.010_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/hepr.13347","article-title":"Emerging novel treatments for autoimmune liver diseases","volume":"49","author":"Tanaka","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2021.04.010_bib9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","article-title":"Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?","volume":"1","author":"Poupon","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.04.010_bib10","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A\u00a0multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis","volume":"324","author":"Poupon","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.04.010_bib11","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.04.010_bib12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","article-title":"Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials","volume":"101","author":"Shi","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.04.010_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.04.010_bib14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.04.010_bib15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.04.010_bib16","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.04.010_bib17","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.04.010_bib18","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.04.010_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.04.010_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhepr.2019.05.005","article-title":"New treatments\/targets for primary biliary cholangitis","volume":"1","author":"Corpechot","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2021.04.010_bib21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.04.010_bib22","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/liv.13344","article-title":"Finding the cure for primary biliary cholangitis - still waiting","volume":"37","author":"Tanaka","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.04.010_bib23","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.31017","article-title":"Liver injury in patients with cholestatic liver disease treated with obeticholic acid","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.04.010_bib24","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary\u00a0cirrhosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.04.010_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1386-6346(99)00033-9","article-title":"Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis","volume":"16","author":"Iwasaki","year":"1999","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2021.04.010_bib26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study","volume":"95","author":"Nakai","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.04.010_bib27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","article-title":"Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis","volume":"29","author":"Itakura","year":"2004","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2021.04.010_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol Res"},{"issue":"Suppl S1","key":"10.1016\/j.jhep.2021.04.010_bib29","first-page":"71","article-title":"Guidelines for the management of primary biliary cirrhosis: the intractable hepatobiliary disease study group supported by the Ministry of Health, labour and Welfare of Japan","volume":"44","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2021.04.010_bib30","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.04.010_bib31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/apt.15049","article-title":"Letter: reduction in projected mortality or need for liver transplantation associated with bezafibrate add-on in primary biliary cholangitis with incomplete UDCA response","volume":"49","author":"Corpechot","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.04.010_bib32","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep.30552","article-title":"Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis","volume":"70","author":"Honda","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.04.010_bib33","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1386-6346(01)00148-6","article-title":"Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC)","volume":"22","author":"Nakano","year":"2002","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2021.04.010_bib34","first-page":"254","article-title":"The efficacy of ursodeoxycholic acid for primary biliary cirrhosis","volume":"64","author":"Wada","year":"1987","journal-title":"Rinsho to Kenkyu"},{"key":"10.1016\/j.jhep.2021.04.010_bib35","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.04.010_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14534","article-title":"A\u00a0validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis","author":"Yagi","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.04.010_bib37","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2021.04.010_bib38","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"5","author":"de Vries","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.04.010_bib39","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0039-1687852","article-title":"Clinical trials in PBC going forward","volume":"39","author":"Corpechot","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2021.04.010_bib40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A\u00a0prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.04.010_bib41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.04.010_bib42","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/liv.14165","article-title":"Additional fibrate treatment in UDCA-refractory PBC patients","volume":"39","author":"Chung","year":"2019","journal-title":"Liver Int"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821002452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821002452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:55:14Z","timestamp":1777510514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821002452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0168827821002452"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.04.010","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}